H.C.R. NO. 194

HOUSE CONCURRENT RESOLUTION

REQUESTING THE DEPARTMENT OF THE ATTORNEY GENERAL TO CONDUCT A STUDY TO DETERMINE IF XYLAZINE TESTING STRIPS SHOULD BE EXCLUDED FROM THE STATE'S DEFINITION OF DRUG PARAPHERNALIA.

WHEREAS, xylazine is a non-opiate sedative, analgesic, and 1 2 muscle relaxant that has been only approved by the United States Food and Drug Administration for veterinary use; and 3 4 5 WHEREAS, xylazine has been increasingly identified as a cutting agent or adulterant in the illicit drug supply, often 6 7 mixed with fentanyl, which increases the risk of a fatal drug 8 overdose; and 9 WHEREAS, as of November 2022, xylazine was found in the 10 illicit drug supply in forty-eight of fifty states and is 11 currently associated with one in ten fatal fentanyl overdoses; 12 13 and 14 15 WHEREAS, although symptoms of xylazine use and opioid use 16 are similar, overdose reversal agents such as naloxone do not counteract the effects of xylazine; and 17 18 19 WHEREAS, there is currently no drug approved by the Food and Drug Administration to reverse the effects of xylazine in 20 21 humans; and 22 23 WHEREAS, in 2023, multiple states considered legislation to schedule xylazine as a controlled substance; and 24 25 WHEREAS, historically state drug paraphernalia laws have 26 27 prohibited the possession of drug-checking equipment, such as 28 fentanyl test strips, which can be used by a person who uses 29 drugs to test their supply for an adulterated substance; and 30

1

Page 2

H.C.R. NO. 194

1 WHEREAS, in order to combat overdose deaths from drugs 2 adulterated by fentanyl, legislatures across the country have 3 altered their drug paraphernalia laws to either explicitly 4 legalize fentanyl test strips or generally legalize drug-5 checking equipment; and 6 7 WHEREAS, similar steps should be taken to combat the rise 8 of drugs adulterated by xylazine; now, therefore, 9 10 BE IT RESOLVED by the House of Representatives of the 11 Thirty-second Legislature of the State of Hawaii, Regular 12 Session of 2024, the Senate concurring, that the Department of 13 the Attorney General is requested to conduct a study to determine if xylazine testing strips should be excluded from the 14 State's definition of drug paraphernalia; and 15 16 17 BE IT FURTHER RESOLVED that the Department of the Attorney 18 General is requested to submit a report of its study, including 19 findings and recommendations, and any proposed legislation, to the Legislature no later than twenty days prior to the convening 20 of the Regular Session of 2025; and 21 22 23 BE IT FURTHER RESOLVED that a certified copy of this 24 Concurrent Resolution be transmitted to the Attorney General. 25 26 MAR 0 8 2024 27 OFFERED BY:

2024-2177 HCR HMSO